NCT03528408View on ClinicalTrials.gov

Study of Adjuvant Ipilimumab and Nivolumab in Subjects With High-risk Ocular Melanoma

PHASE2UnknownINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

July 26, 2018

Primary Completion Date

May 31, 2023

Study Completion Date

June 30, 2023

Conditions
MelanomaOcular Melanoma
Interventions
DRUG

Nivolumab

Nivolumab 240 mg IV over 30 minutes given Day 1, 15 and 29 of each Cycle

DRUG

Ipilimumab

Ipilimumab 1 mg/kg IV over 60 minutes given Day 1 of each Cycle

Trial Locations (6)

10032

Columbia University, New York

20057

Georgetown University, Washington D.C.

60611

Northwestern Univeristy Feinberg School of Medicine, Chicago

63110

Washington University School of Medicine, St Louis

77030

MD Anderson Cancer Center, Houston

94158

University of California San Francisco, San Francisco

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Suthee Rapisuwon

OTHER